NASDAQ:SLDB

Solid Biosciences Q3 2025 Earnings Results & Report

Solid Biosciences logo
$6.23 -0.25 (-3.86%)
Closing price 04:00 PM Eastern
Extended Trading
$6.24 +0.01 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Solid Biosciences missed analyst earnings expectations in its Q3 2025 results, released November 3, 2025. The company reported EPS of -$0.48 versus the -$0.42 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
2:00 AM ET

Solid Biosciences EPS Results

Actual EPS
-$0.48
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Solid Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Solid Biosciences Q3 2025 Earnings FAQ

Solid Biosciences (NASDAQ:SLDB) reported earnings of -$0.48 per share for Q3 2025, missing the consensus estimate of -$0.42. The report was announced on Monday, November 3, 2025.

Solid Biosciences Earnings Headlines

William Blair Begins Coverage on Solid Biosciences (NASDAQ:SLDB)
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Solid Biosciences (SLDB) Gets a Buy from RBC Capital
See More Solid Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Solid Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Solid Biosciences and other key companies, straight to your email.

About Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is a biotechnology company developing genetic medicines for Duchenne muscular dystrophy and other serious neuromuscular and cardiac diseases. The company’s research focuses on gene-transfer approaches intended to address underlying causes of these conditions.

Its lead program, SGT-003, is an investigational gene therapy being developed for Duchenne muscular dystrophy. Solid Biosciences also has research programs targeting other rare diseases. These programs are in development, and its therapies have not been established as approved treatments.

Founded in 2013 and based in the United States, Solid Biosciences conducts research and clinical development in the rare-disease field. Its work includes evaluating investigational treatments through clinical studies.

View Solid Biosciences Profile